Opinion

Video

Applying Trial Data to Real-World Practice in ALK+ NSCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Elizabeth Castronovo, NP

Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).

Real-World Settings and Evolution of Frontline Therapy

Key Themes:

  • Comparison of clinical trial outcomes to real-world patient experiences
  • Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices
  • Evolving perspective on frontline therapies for ALK+ NSCLC

Notable Insights:

  • Grizzard addressed how well outcomes from trials like CROWN and eXalt3 reflect real-world patient experiences

Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Related Content
White blood cells | Image credit: Sebastian Kaulitzki - stock.adobe.com
July 2nd 2025

Basophil, Eosinophil Counts Could Be Prognostic Indicators in ET, PV

Jared Kaltwasser
The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Multiple myeloma words appearing on table | Image credit: ibreakstock - stock.adobe.com
July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

Jared Kaltwasser
The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Joshua K. Sabari, MD | Image: NYU Langone
Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey
Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Outside of patient diversity, the researchers call for variety in data types to strengthen AI models, with a compilation of patient records with genomic data and images. | Image credit: natali_mis - stock.adobe.com
July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor
While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo
OSZAR »